![Meike Heurich-Sevcenco](https://profiles-cardiff.imgix.net/attachments/2919?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Meike Heurich-Sevcenco
Senior Lecturer
- Ar gael fel goruchwyliwr ôl-raddedig
Trosolwyg
Fe ddechreuais yn Ddarlithydd yn Yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ym mis Ionawr 2017.
Fe hyfforddais yn Fiocemegydd (yr Almaen, 2003) ac enillais fy PhD (DU, 2008) ym maes Biocemeg Gymhwysol a datblygu Biosynhwyryddion.
Dechreuais weithio ym maes ymchwil Ategu yn 2008 yn ymchwilydd ôl-ddoethurol yng ngrŵp Bioleg Ategu (Complement Biology) yr Athro C Harris a'r Athro P Morgan yn yr Ysgol Meddygaeth, Prifysgol Caerdydd.
Yn 2012, dyfarnwyd cymrodoriaeth datblygu gyrfa annibynnol i mi (NISCHR, Ymchwil Iechyd a Gofal Cymru erbyn hyn) i ymchwilio i fecanwaith y cydgysylltu (crosstalk) a geir rhwng y broses ategu â’r system geulo, gan weithio gyda'r Athro P Collins yn Ysgol Meddygaeth, Caerdydd. Yno, sefydlais grŵp ymchwil annibynnol ym maes ymchwil Ategu a Cheulo.
Yn 2017, symudais fy labordy ymchwil i'r Ysgol Fferylliaeth, Caerdydd, lle rwy'n arwain grŵp sy'n canolbwyntio ar ddarganfod a dogfennu nodweddion swyddogaethol y cydgysylltu moleciwlaidd a geir o ran proteinau gwaed, ac yn bennaf felly o ran y llwybrau ategu a cheulo. Rwyf hefyd yn ymchwilio i bathoffisioleg y llwybrau hyn o ran clefydau.
Yn rhan o fy ngwaith rwyf hefyd yn gwneud gwaith dadansoddi biofarcwyr ar gyfer cydrannau ategu a cheulo a'u cynhyrchion actifadu ym mhlasma’r gwaed, o ran clefydau. Yn ogystal, rwy'n ymgymryd â sgrinio moleciwlau bach ar gyfer darganfod a dogfennu nodweddion ar gyfer therapiwteg serin proteas wedi'i dargedu.
Geiriau allweddol: system imiwnedd gynhenid, ategu; ceulo
Cyhoeddiad
2024
- Heurich, M., Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39, article number: 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al. 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119, pp. 188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al. 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10, article number: 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al. 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50(3), pp. 579-588. (10.1093/schbul/sbad184)
- Healy, C. et al. 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117, pp. 175-180. (10.1016/j.bbi.2023.12.018)
2023
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228(6), article number: 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V., Kittel, M., Heurich-Sevcenco, M., Föcking, M., Leweke, F. and Pantelis, C. 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113, pp. 136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al. 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49(4), pp. 893-902. (10.1093/schbul/sbac201)
2022
- Susai, S. R. et al. 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12, article number: 454. (10.1038/s41398-022-02217-0)
- Heurich, M., Föcking, M., Mongan, D., Cagney, G. and Cotter, D. R. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27, pp. 127-140. (10.1038/s41380-021-01197-9)
2021
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N., Szakmany, T., Hall, J. E. and Heurich, M. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10(22), article number: 5391. (10.3390/jcm10225391)
- Howes, O., Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90(9), pp. 593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al. 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13(2), article number: 312. (10.3390/v13020312)
- Mongan, D. et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78(1), pp. 77-90. (10.1001/jamapsychiatry.2020.2459)
2019
- Madrid-Gambin, F. et al. 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86(1), pp. 25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al. 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26, pp. 524-533. (10.1038/s41380-018-0306-z)
2016
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
2015
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71(2), pp. 147-149. (10.1016/j.jinf.2015.04.019)
2014
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols., Vol. 1100. Methods in Molecular Biology Humana Press, pp. 75-91., (10.1007/978-1-62703-724-2_6)
2013
- Heurich, M., Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5(6), pp. 1202-1218. (10.3390/toxins5061202)
2012
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
2011
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
2010
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
Adrannau llyfrau
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols., Vol. 1100. Methods in Molecular Biology Humana Press, pp. 75-91., (10.1007/978-1-62703-724-2_6)
Erthyglau
- Heurich, M., Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39, article number: 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al. 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119, pp. 188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al. 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10, article number: 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al. 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50(3), pp. 579-588. (10.1093/schbul/sbad184)
- Healy, C. et al. 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117, pp. 175-180. (10.1016/j.bbi.2023.12.018)
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228(6), article number: 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V., Kittel, M., Heurich-Sevcenco, M., Föcking, M., Leweke, F. and Pantelis, C. 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113, pp. 136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al. 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49(4), pp. 893-902. (10.1093/schbul/sbac201)
- Susai, S. R. et al. 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12, article number: 454. (10.1038/s41398-022-02217-0)
- Heurich, M., Föcking, M., Mongan, D., Cagney, G. and Cotter, D. R. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27, pp. 127-140. (10.1038/s41380-021-01197-9)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N., Szakmany, T., Hall, J. E. and Heurich, M. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10(22), article number: 5391. (10.3390/jcm10225391)
- Howes, O., Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90(9), pp. 593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al. 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13(2), article number: 312. (10.3390/v13020312)
- Mongan, D. et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78(1), pp. 77-90. (10.1001/jamapsychiatry.2020.2459)
- Madrid-Gambin, F. et al. 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86(1), pp. 25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al. 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26, pp. 524-533. (10.1038/s41380-018-0306-z)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71(2), pp. 147-149. (10.1016/j.jinf.2015.04.019)
- Heurich, M., Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5(6), pp. 1202-1218. (10.3390/toxins5061202)
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
Ymchwil
Meysydd ymchwil
- Mecanweithiau traws-sgwrsio ategu a cheulo mewn iechyd a chlefydau.
- Llwybrau ategu a cheulo mewn seicosis
- Biofarcwyr gwaed
- Therapiwteg ategol
Mae fy ymchwil blaenorol wedi canolbwyntio'n bennaf ar nodweddu swyddogaeth a swyddogaeth protein sy'n arwain at ddadreoleiddio'r system ategol, rhan o'r amddiffyniad imiwnedd cynhenid, gan gynnwys y complotype.
https://doi.org/10.1016%2Fj.molimm.2015.03.248
https://doi.org/10.1016%2Fj.it.2012.06.001
https://doi.org/10.1073%2Fpnas.1019338108
https://doi.org/10.1172%2Fjci43343
Mae fy labordy ymchwil yn yr Ysgol Fferylliaeth yn ymchwilio i’r traws-sgwrsio moleciwlaidd rhwng y ddwy system amddiffyn gynhenid rhag ymlediad pathogenau a gwaedu, sef ategu a cheulo. Mae systemau ategu a cheulo yn rhaeadrau protein tebyg yn strwythurol ac yn drefniadol sy'n cael eu hysgogi gan sbardunau diffiniedig, yn aml ochr yn ochr.
Mae dadreoleiddio'r systemau hyn wedi bod yn gysylltiedig â llawer o glefydau â phatholeg sy’n hybu llidio ac sy’n hybu ceulo.
Ar hyn o bryd rydym yn astudio traws-sgwrsio ategu a cheulo ar y lefel protein a chellog in vitro ac yn ymchwilio i fecanweithiau in vivo.
Mae prosiectau cyfredol yn cynnwys:
i) Rydym yn gweithio gyda chydweithwyr clinigol yn yr Ysgol Feddygaeth ac Ysbyty Athrofaol Cymru Caerdydd. Rydym yn dadansoddi effaith ffactor cyflenwol H ar swyddogaeth ceulo gan adeiladu ar waith blaenorol sy’n nodweddu traws-sgwrsio rheoleiddiwr ceulo thrombomodulin â rheolydd ategol ffactor H.
https://doi.org/10.1016%2Fj.thromres.2016.07.017
Gellir gweld ein gwaith diweddaraf sy’n disgrifio "Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles" yn destun llawn cyn-argaffu: https://www.biorxiv.org/content/10.1101/2021.07.22.452893v1
ii) Mewn cydweithrediad â chydweithwyr yn RCSI Dulyn mae fy labordy yn astudio effaith actifadu ategu a cheulo ar unigolion sy'n symud ymlaen i gael profiadau seicotig neu anhwylderau seicotig.
https://doi.org/10.1038/s41380-018-0306-z
https://doi.org/10.1016/j.biopsych.2019.01.018
https://doi:10.1001/jamapsychiatry.2020.245
Mae fy erthygl adolygu ddiweddaraf "Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis" yn disgrifio rolau annatod y llwybrau hyn a gludir yn y gwaed yn natblygiad seicosis. Gallwch weld yr erthygl adolygu yma:https://www.nature.com/articles/s41380-021-01197-9
Rydym hefyd yn y NEWYDDION. Gweler isod.
Cyfleoedd i fyfyrwyr ôl-ddoethurol
Dyfarnwyd cyllid Ymddiriedolaeth Wellcome i Dr Heurich ar gyfer swydd ôl-ddoethurol yn ei labordy gan ddechrau yn 2021.
Mae sgitsoffrenia ymhlith yr anhwylderau drutaf o ran ansawdd bywyd a chost cymdeithasol ac mae angen dybryd i wella ein dealltwriaeth o'r rhyngweithio rhwng ffactorau genynnol ac amgylcheddol sy'n bwysig yn y clefyd. Rydym yn ymchwilio i fiofarcwyr protein plasma seicosis gan ddefnyddio dulliau’n seiliedig ar sbectrometreg màs a biocemeg. Rydym yn defnyddio samplau sy'n unigryw yn rhyngwladol, y byddwn yn eu defnyddio ar gyfer astudiaethau darganfod a dilysu. Bydd yr ymgeisydd llwyddiannus yn cydweithio’n agos â labordy proteomeg Dr Gerard Cagney yng Ngholeg Prifysgol Dulyn a labordy’r Athro David Cotter yn RSCI Dulyn (gweler uchod am brosiectau cydweithredol a chyhoeddiadau, ii)
Ar hyn o bryd rydym yn chwilio am gydymaith ymchwil ôl-ddoethurol i ymuno â thîm y prosiect dan arweiniad Dr Meike Heurich yn Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd sy'n astudio biofarcwyr plasma gwaed swyddogaethol i ddadansoddi'r risg o drosglwyddo o risg uchel clinigol i anhwylder seicotig. Ariennir y prosiect ymchwil hwn gan Raglen Flaenllaw Arloesedd Ymddiriedolaeth Wellcome.
Dyddiad cychwyn yng Ngwanwyn/Haf 2021 (swydd wag /hysbyseb i'w gyhoeddi).
Os oes gennych ymholiadau pellach, ebostiwch heurichm@caerdydd.ac.uk
MAE UNIGOLYN BELLACH WEDI'I BENODI I'R SWYDD HON.
Cyfleoedd PhD
(PROSIECT YR YDYCH YN EI ARIANNU EICH HUN)
Mae Dr Heurich gyda'r Athro Collins (Ysgol Meddygaeth, Caerdydd) yn cynnig cyfle i fyfyrwyr PhD. Sylwch, prosiect yr ydych yn ei ariannu eich hun fydd hwn.
Nodweddu'r rhyngweithio rhwng ceulo ac imiwnedd cynhenid ymhlith pobl sy'n cael eu trin am anhwylder gwaedu hemoffilia A
Mae triniaeth newydd ar gyfer cleifion hemoffilia wedi bod yn gysylltiedig â thrombosis mewn pibellau gwaed bach yn yr aren. Mae hyn hefyd i'w gael mewn anhwylder arennau prin a achosir gan nam ar swyddogaeth imiwnedd proteinau gwaed. Bydd y prosiect hwn yn pennu mecanweithiau'r driniaeth hon ar geulo a'r system imiwnedd trwy brofion in vitro a samplau clinigol.
Os oes gennych ymholiadau pellach, ebostiwch heurichm@caerdydd.ac.uk
Beth sy'n digwydd yn labordy Heurich:
Dyma’r ddolen i gyngres ISTH 2020 ( https://www .isth2020.org/ ), lle dewiswyd ein crynodeb ar gyfer cyflwyniad llafar, a draddodwyd gan Genevieve McCluskey, myfyriwr PhD.
https://academy.isth.org/isth/2020/milan/303436/enevieve.mccluskey.complement.regulator.factor.h.is.a.cofactor.for.thrombin.html?f=listing%3D4%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D788727%2Ace_id%3D1697%2Atopic%3D21498
Dyma'r ddolen i gyfweliad uchafbwyntiau ISTH:
https://isth.totalcme.com/Articles/ArtMID/3695/ArticleID/45/Complement-Regulator-Factor-H-Is-a-Cofactor-for-Thrombin-in-Both-Pro-and-Anticoagulant-Roles#.XwyKjMr08wY.linkedin
Dyma’r ddolen i gyfarfod Complement UK 2021, lle dewiswyd ein crynodeb ar gyfer cyflwyniad llafar a poster. Cyflwynodd Genevieve McCluskey, myfyriwr PhD y cyflwyniad llafar ac enillodd y wobr. Llongyfarchiadau!
https://complement.org.uk/conference/
Digwyddiadau diweddar a NEWYDDION
Gorffennaf
Rydym yn falch o roi rhagflas o'n hymchwil cyffrous diweddaraf "Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles" yn destun llawn cyn-argaffu: https://www.biorxiv.org/content/10.1101/2021.07.22.452893v1
Rydym yn falch o gyhoeddi ein hadolygiad "Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis" yn disgrifio rolau annatod y llwybrau hyn a gludir yn y gwaed yn natblygiad seicosis. Gallwch weld yr erthygl adolygu yma:https://www.nature.com/articles/s41380-021-01197-9
Gellir gweld NEWYDDION perthnasol yma:
https://www.rcsi.com/dublin/news-and-events/news/news-article/2021/07/new-theory-suggests-changes-in-blood-immune-and-clotting-components-could-contribute-to-psychosis
https://www.sciencedaily.com/releases/2021/07/210716112446.htm
https://www.psychiatrictimes.com/view/blood-clotting-immune-system-psychosis
https://neurosciencenews.com/blood-immune-clotting-psychosis-18932/
Ebrill
Dr Meike Heurich yn rhoi cyflwyniad llafar yn Sesiwn 5 ar 1 Ebrill 2021 yn Wythnosau Gwyddoniaeth Hemostasis rhithwir 2021.
https://www.siemens-healthineers.com/news-and-events/conferences-events-new/hemostasis-science-weekstps://live.hemostasis-science-weeks.siemens-healthineers-events.com/
Symposiwm SPR 2021. Bydd ein rhith Symposiwm SPR Biacore ar 20 Ebrill 2020 o 13.30pm yn dod â gwyddonwyr ynghyd i rannu a gwella eu gwybodaeth am dechnoleg Cyseiniant Plasmon Arwyneb Biacore (SPR) ar gyfer dadansoddi ystod o ryngweithiadau biomoleciwlaidd.
Ar gyfer cofrestru a manylion:
https://www.cardiff.ac.uk/events/view/2501591-biacore-spr-symposium-2021
a drefnwyd gan Wasanaethau Biotechnoleg Canolog Caerdydd a Dr Meike Heurich.
--------------------------------
Gobeithiwn fod y symposiwm SPR rhithwir ar yr 20fed o Ebrill o ddiddordeb i chi - ac wedi eich ysbrydoli i ddechrau meddwl sut y gallwch ddefnyddio technoleg SPR-Biacore ar gyfer eich gwaith!
Mae CBS Caerdydd yn cynnal digwyddiad rhithwir arall rhad ac am ddim sy'n canolbwyntio ar gymhwyso a hyfforddiant SPR/BIACORE a gyflwynir gan arbenigwr Biacore, John Sinfield:
'Diwrnod Hyfforddiant Cais Symposiwm SPR Biacore gan Cytiva (a gynhelir gan CBS) ' ddydd Mawrth 11 Mai.
Dyma'r ddolen i gofrestru:
https://www.eventbrite.co.uk/e/biacore-spr-symposium-application-training-day-by-cytiva-hosted-by-cbs-tickets-150773614941
Os oes gennych unrhyw gwestiynau, cysylltwch â mi ar bob cyfrif.
------------------------------
Digwyddiadau ar y gweill
Adolygiadau Arbenigol mewn Meddygaeth Foleciwlaidd - Galwad am bapurau
https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/information/call-for-papers
Adolygiadau Arbenigol mewn Meddygaeth Foleciwlaidd - Gweminarau awduron
https://www.cambridge.org/core/journals/expert-reviews-in-molecular-medicine/information/author-webinars
Addysgu
Cyrsiau
MPharm
- MSc Bioleg Canser
- MSc Ymchwil Glinigol
- Darlithoedd
Arweinydd y Modiwl, Modiwl PH1123: Biocemeg, Microbioleg, Bioleg celloedd
- MODIWL PH1123: Strwythur a swyddogaeth celloedd - Bioleg Celloedd
- MODIWL PH1124: Systemau'r corff dynol - Imiwnoleg Sylfaenol
- MODIWL PH2113: Cyffuriau a Chlefydau 1 - Imiwnoleg Glinigol
- MODIWL PH3113: Cyffuriau a Chlefydau 2 - Rhewmatoleg
- PHT801 Bioleg Cellau a Moleciwlau Canser - Imiwnoleg
- PHT801 Bioleg Cellau a Moleciwlau Canser - Imiwnotherapi
- PHT804 MSc Bioleg Canser - Dulliau Ymchwil
- PHT202 MSc Ymchwil Glinigol - Imiwnoleg
Ymarferol
- MODIWL PH1124: Anatomeg Sylfaenol
- MODIWL PH1124: Ffarmacoleg
Gweithdai
- PH1124: Imiwnoleg clefydau
- PHT801: Imiwnotherapi yn ymwneud â Chanser
- PHT804: Methodoleg Ymchwil, bioffiseg, cyseiniant plasmon arwynebau
Arall
Cymorth addysgu ac addysgu nad yw'n ymwneud â modiwlau, goruchwylio myfyrwyr ymchwil ôl-raddedig (PhD, MSc)
Bywgraffiad
01/2017 – PRESENNOL Darlithydd (Addysgu ac Ymchwil, penagored)
Ymchwil mewn Biocemeg Protein a Therapiwteg Arbrofol, Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Fferylliaeth a Gwyddorau Fferyllol, Prifysgol Caerdydd, y DU.
06/2016 -12/2016 Uwch Ôl-ddoethuriaeth mewn Firoleg Foleciwlaidd, Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Meddygaeth, Sefydliad Heintiau ac Imiwnedd, Prifysgol Caerdydd, y DU, “Developing human cytomegalovirus (CMV) for expansion of CD8+ T Cells with improved in vivo lifespan for immunotherapy”.
09/2013 — 08/2014 Secondiad Darlithydd (Meddygaeth Glinigol, rhan amser ochr yn ochr â chymrodoriaeth datblygu gyrfa), Ysgol Meddygaeth, Prifysgol Caerdydd, y DU
03/2012 — 06/2016 Cymrodoriaeth Ymchwil Datblygu Gyrfa mewn Biocemeg Protein Gwaed, Sefydliad Heintiau ac Imiwnedd, Ysgol Meddygaeth, Prifysgol Caerdydd, y DU. “Cross-interaction of the innate immune response (complement system) with coagulation proteins in blood disorders”.
09/2011 — 02/2012 Ôl-ddoethuriaeth/Cydymaith Ymchwil mewn Bioleg Ategol, Sefydliad Meddygaeth Seicolegol a Niwrowyddorau Clinigol a Sefydliad Heintiau ac Imiwnedd, Ysgol Meddygaeth, Prifysgol Caerdydd, y DU. “The role of complement receptor CR1 in Alzheimer’s disease”.
09/2008 — 08/2011 Ôl-Ddoethuriaeth/Cydymaith Ymchwil mewn Bioleg Ategu, Adran Heintiau, Imiwnedd a Biocemeg, Ysgol Meddygaeth, Prifysgol Caerdydd, y DU. “The role of complement dysregulation in disease” & “The Complotype: dictating risk for inflammation and infection”.
04/2007-07/2008 Cynorthwyydd Ymchwil mewn Bioleg Ategol, Adran Biocemeg Feddygol, Ysgol Meddygaeth, Prifysgol Caerdydd, y DU.
Addysg
04/2004 — 04/2008 PhD mewn Ymchwil Biocemegol a Bioffisegol, Canolfan Biotechnoleg Cranfield, Prifysgol Cranfield, y DU. “Development of a screen-printed, voltammetric electrochemical biosensor for the immunosuppressant mycotoxin ochratoxin A”.
03/2003 — 09/2003 Traethawd ymchwil Meistr, Sefydliad Biofeddygaeth a Chemeg, Prifysgol Kalmar, Sweden. “Development of a diagnostic tool for markers of ischemic heart disease for early diagnosis of acute myocardial infarction”.
10/1997 — 09/2003 Diploma mewn Biocemeg, Yr Almaen
Anrhydeddau a dyfarniadau
02/2012 Gwobr Cymrodoriaeth Ymchwil Datblygu Gyrfa, NISCHR (Ymchwil Iechyd a Gofal Cymru erbyn hyn)
12/2010 Gwobr Gwyddonydd Ifanc y Flwyddyn, Cymdeithas Imiwnoleg Prydain
Aelodaeth o gyrff proffesiynol
2017 – presennol Cymdeithas Haematoleg Ewrop
2012 - presennol Cymdeithas Ryngwladol ar Thrombosis a Haemostasis
2009 - presennol Cymdeithas Imiwnoleg Prydain
2008 - presennol Cymdeithas Gyflenwol Ryngwladol
2005 - presennol Cymdeithas Biocemegol, y DU
Anrhydeddau a dyfarniadau
02/2012 Career Development Research Fellowship Award, NISCHR (now Health and Care Research Wales)
12/2010 Young Scientist of the Year Award, British Society for Immunology
Aelodaethau proffesiynol
2017 – present European Haematology Association
2012 – present International Society on Thrombosis and Haemostasis
2009 – present British Society for Immunology
2008 – present International Complement Society
2005 – present Biochemical Society, UK
Meysydd goruchwyliaeth
Protein Biochemistry
Protein-protein interaction
Complement Biology
Blood proteins of the immune and coagulation systems
Blood proteins in the pathophysiology of disease
Contact Details
+44 29208 76657
Adeilad Redwood , Ystafell 2.57B, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
